Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity by Severini, C. et al.
1Scientific RepoRts | 5:15301 | DOi: 10.1038/srep15301
www.nature.com/scientificreports
Bv8/prokineticin 2 is involved in 
Aβ-induced neurotoxicity
Cinzia Severini1,2,*, Roberta Lattanzi3,*, Daniela Maftei3, Veronica Marconi3, Maria 
Teresa Ciotti1, Pamela Petrocchi Passeri1, Fulvio Florenzano2, Ester Del Duca2, 
Silvia Caioli4,5, Cristina Zona4,5, Gianfranco Balboni6, Severo Salvadori7, Robert Nisticò2,4 & 
Lucia Negri3
Bv8/Prokineticin 2 (PROK2) is a bioactive peptide initially discovered as a regulator of gastrointestinal 
motility. Among multiple biological roles demonstrated for PROK2, it was recently established 
that PROK2 is an insult-inducible endangering mediator for cerebral damage. Aim of the present 
study was to evaluate the PROK2 and its receptors’ potential involvement in amyloid beta (Aβ) 
neurotoxicity, a hallmark of Alzheimer’s disease (AD) and various forms of traumatic brain injury 
(TBI). Analyzing primary cortical cultures (CNs) and cortex and hippocampus from Aβ treated rats, 
we found that PROK2 and its receptors PKR1 and PKR2 mRNA are up-regulated by Aβ, suggesting 
their potential involvement in AD. Hence we evaluated if impairing the prokineticin system activation 
might have protective effect against neuronal death induced by Aβ. We found that a PKR antagonist 
concentration-dependently protects CNs against Aβ1–42-induced neurotoxicity, by reducing the 
Aβ-induced PROK2 neuronal up-regulation. Moreover, the antagonist completely rescued LTP 
impairment in hippocampal slices from 6 month-old Tg2576 AD mice without affecting basal synaptic 
transmission and paired pulse-facilitation paradigms. These results indicate that PROK2 plays a role 
in cerebral amyloidosis and that PROK2 antagonists may represent a new approach for ameliorating 
the defining pathology of AD.
Alzheimer’s disease (AD) is an irreversible/chronic progressive neurodegenerative disease, characterized 
by extracellular deposition of Aβ plaques and intracellular accumulation of hyper-phosphorylated tau 
protein in neurofibrillary tangles1.
Substantial evidence indicates that Aβ plaque processes might be the central players in AD pathol-
ogy2,3. Senile plaques are intimately surrounded by morphologically abnormal dendrites and axons and 
are infiltrated by astrocytes and microglia in and around their central amyloid core4,5. Once activated, 
astrocytes and microglia produce several pro-inflammatory signal molecules, including cytokines, growth 
factors, complement molecules, cell adhesion molecules and chemokines6. This activation is thought to 
result from the glial reaction to the events related to the ongoing deposition of Aβ 7,8, leading to an 
inflammatory hypothesis6. Indeed, analysis of human brain AD samples has revealed highly expressed 
inflammatory cytokines during the early stages of AD, and genome-wide studies showed an up-regulation 
of inflammatory genes, indicating a potential role of inflammation in the progression of AD9.
Chemokines are a group of cytokines originally identified as factors regulating the migration of leuko-
cytes in inflammatory and immune responses10. While it has been reported that chemokines exert physi-
ological actions in the healthy brain11, they have been shown to be produced under various pathological 
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conditions including AD12,13. To confirm these data, several chemokines and chemokine receptors have 
been found to be up-regulated in the AD brain14.
A new family of chemokines, the Bv8/Prokineticin family has recently emerged as a critical player 
in immune system and inflammatory diseases. They are secreted bioactive peptides highly conserved 
across species15,16. In mammals, this family consists of two ligands: EG-VEGF/prokineticin1 (PROK1) 
and mammalian-Bv8/PROK2 and of two G-protein coupled receptors: PKR1 and PKR2. The amphibian 
homologue, Bv8, isolated from the skin secretion of the frog Bombina variegata displayed pharmaco-
logical activity like the mammalian molecule PROK2, with comparable affinity for both receptors17. Bv8 
also represents a good pharmacological tool to study the effect of PROK2 in vitro and in vivo, as we have 
already demonstrated18–20. Since their discovery, multiple physiological roles for the prokineticins have 
been evidenced. Accordingly, they were shown to promote angiogenesis and modulate neurogenesis, 
circadian rhythms, hematopoiesis, and immune response19.
The prokineticin receptors, PKR1 and PKR2 are localized in the brain, dorsal root ganglia (DRG) neu-
rons, granulocytes, macrophages, and endothelial cells. The agonist PROK2 is expressed in discrete nuclei 
into the brain20 and is constitutively expressed, at very low levels, in some DRG neurons21,22, in bone 
marrow, spleen and in peripheral blood cells but it is strongly up-regulated in inflammatory diseases and 
tumours, associated with infiltrating cells18,23,24. We have recently demonstrated that peripheral nerve 
injury causes a dramatic increase of PROK2 in DRG neurons and in activated astrocytes in the spinal 
cord, associated with development of neuropathic pain22 and identified PROK2 as a critical mediator of 
experimental autoimmune encephalomyelitis (EAE), animal model of Multiple Sclerosis25.
Recently, it was demonstrated that PROK2 is an insult-inducible endangering mediator for cerebral 
ischemic injury, identifying this bioactive peptide as a potential therapeutic target for stroke, supporting a 
role in brain pathological states26. Given that mRNA PROK2 expression is up-regulated by several patho-
logical stressors, including hypoxia, reactive oxygen species, and excitotoxic glutamate, here we investi-
gated if Aβ , the central player in AD, might induce a pathological condition leading to over-expression 
of the prokineticin system.
To this aim, we examined the expression profile of PROK2, PKR1 and PKR2 at basal conditions and 
after Aβ insult in vitro, in primary cortical cultures, and in vivo, in a non-transgenic rat model of AD 
obtained by intracerebroventricular (i.c.v.) injection of Aβ .
Furthermore, we investigated the potential neuroprotective effect resulting from the pharmacological 
blockade of the prokineticin system. Our data suggest that Aβ induces activation of the prokineticin 
system which may represent a new pathological hallmarks in animal models and possibly a novel ther-
apeutic target for AD.
Results
Aβ-induced neuronal apoptosis in primary cortical cultures. Incubation of cortical cultures 
(CNs) with Aβ 1–42 for 48 h reduced cell survival in a concentration-dependent manner. As shown in 
Fig. 1A, 20 μ M of Aβ 1–42 induced about 50% reduction in cells viability and this concentration was cho-
sen to investigate a possible involvement of the prokineticin system in Aβ -induced toxicity. To character-
ize the identity of the dying cells, we quantified the number of dying neurons (NeuN-positive cells) and 
of dying astrocytes (GFAP-positive cells) following Aβ 1–42 treatment (20 μ M). The amount of NeuN+ cells 
decreased of about 50% (710 ± 95 in control group vs 290 ± 31 in Aβ treated cultures) while number of 
GFAP+ cells was not affected (560 ± 65 in control group vs 522 ± 87 in Aβ treated cultures), thus demon-
strating that Aβ toxicity is mainly directed to neurons. To confirm that Aβ exerts its toxicity through 
an apoptotic mechanism, we analyzed, by Western blot analysis, the appearance of the caspase 3 active 
fragment. As shown in Fig. 1B, following Aβ 1–42 treatment, this fragment was detected.
Up-regulation of PROK2, PKR1 and PKR2 expression by Aβ insult. Using qRT-PCR, we exam-
ined mRNA expression levels of PROK2 and of its receptors PKR1 and PKR2 in primary cortical cultures 
treated with Aβ 1–42 (20 μ M) at different time-points. Time-course analysis (6, 12, 24 h) indicated that 
PROK2 mRNA was significantly increased after 6 h Aβ 1–42 treatment, and returned to basal levels at 12 
and 24 h.
Both PKR1 and PKR2 mRNA were considerably increased after 24 h treatment (Fig. 2A–C). In order to 
assure about measuring significant levels of transcript we report the Ct values (mean ± SEM, 5 samples) 
for vehicle-treated cultures: PROK2 28.1 ± 0.3; PKR1 32.5 ± 0.8; PKR2 31.6 ± 0.6.
Next, we examined the expression levels of PROK2 and its receptors in rat cortex and hippocampus 3, 
6, 24 and 48 h after i.c.v. injection of Aβ 1–42. In the cortex, time-course analysis indicated about two-fold 
increase in PROK2 expression after 6 h (Fig.  2D). PKR1 mRNA was significantly increased after 6 and 
24 h, whereas PKR2 mRNA showed a biphasic pattern of expression, with a decrease at 6 h followed by 
an increase at 24 and 48 h (Fig.  2E,F). In hippocampus, PROK2 expression increased earlier, showing 
a peak at 3 h after Aβ 1–42 injection (Fig. 2G). The Ct values in control animals (5 animals/group) were: 
in the cortex: 32.1 ± 0.2; 31.9 ± 0.7; 32.4 ± 0.6; 31.8 ± 0.4; 31.7 ± 0.3 at time 0, 3, 6, 24 and 48 h; in hip-
pocampus: 32.8 ± 0.4; 32.1 ± 0.3; 32.6 ± 0.5; 31.9 ± 0.6; 32.1 ± 0.7 at time 0, 3, 6, 24 and 48 h.
The expression of PKR1 and PKR2 showed a similar pattern in hippocampus as in cerebral cortex, with 
an increase of PKR1 at 6 h and a biphasic pattern of expression for PKR2, with a decrease at 6 h followed 
by an increase at 24 and 48 h (Fig. 2H,L). The Ct values in control animals (5 animals/group) were: in 
www.nature.com/scientificreports/
3Scientific RepoRts | 5:15301 | DOi: 10.1038/srep15301
the cortex PKR1 34.8 ± 0.3; 34.1 ± 1.4; 35.3 ± 0.4; 35.8 ± 0.7; 34.5 ± 0.5 and PKR2 31.7 ± 0.2; 31.8 ± 1.5; 
31.3 ± 0.9; 32.3 ± 0,6; 32.6 ± 0.4. In hippocampus PKR1 34.4 ± 0.5; 34.3 ± 0.4; 34.9 ± 0.3; 34.1 ± 0.7; 
34.2 ± 0.8 and PKR2 32.5 ± 0.3; 32.3 ± 0.4; 31.9 ± 0.8; 32.5 ± 0.6; 32.3 ± 0.3 at time 0, 3, 6, 24 and 48 h.
The reported Ct values indicate that the constitutive basal expression of PKR2 is always higher than 
that of PKR1.
Localization of PROK2 and its receptors in CNs after Aβ treatment. By immunofluorescence 
studies we looked for protein localization of PROK2 and its PKRs on neurons and astrocytes of primary 
mixed cortical cultures. Under control conditions, PROK2 immunoreactivity is present in body neurons 
(NeuN + cells) and in astrocytes processes (GFAP+ cells) (Fig. 3A,B), while PKR1 and PKR2 immuno-
reactivity were virtually undetectable (Fig. 3E–J). 12 h, 24 h and 48 h Aβ 1–42 treatment time-dependently 
increased PROK2 in both neurons and astrocytes (Additional Fig. 1 and 3). After 48 h treatment PROK2 
immunoreactivity was localized mainly into cell bodies (Fig. 3C,D). Time discrepancy between PROK2 
mRNA (6 h) and protein (24–48 h) maximum increase might depend on accumulation of the synthesized 
protein into cortical neurons and astrocytes.
Conversely, PKR1 immunoreactivity appeared specifically increased in neuron (arrows) but not in astro-
cyte (arrowhead) cell bodies and localized to perinuclear structures resembling the endoplasmic-Golgi 
membranes complex (Fig. 3G,H). PKR2 immunoreactivity appeared increased and localized to both neu-
ronal cell bodies and astrocytes (Fig. 3K,L), with a diffuse vesiculate cytoplasmatic pattern (arrows).
Effects of PC1, a PKRs antagonist, on Aβ-induced toxicity. Given that Aβ exposure clearly 
induced activation of the prokineticin system, we tested the activity of PC1, a non-peptide Bv8 antag-
onist, against Aβ 1–42 toxicity in primary cortical cultures (CNs). Different concentrations of PC1 were 
co-applied with Aβ 1–42 (20 μ M) to CNs for 48 h. Quantitative analysis revealed that incubation of CNs 
with Aβ 1–42 for 48 h caused ~ 50% reduction in the number of surviving cells, as compared to vehicle 
treated cells (controls, CTR). PC1 (50, 100, 250 and 500 nM) dose-dependently reversed the Aβ 1–42 toxic-
ity, inducing 15.5 ± 5.0%, 37.6 ± 1.9%, 39.5 ± 3.2 and 39.6 ± 11.3% increase in cell viability, as compared 
to Aβ condition (Fig. 4A).
The results obtained were confirmed by cell viability quantification by Hoechst staining, indicating the 
same percentage acquired counting intact nuclei. As shown in Fig. 4B, Aβ 1–42 (20 μ M) induced apoptotic 
cell death with nuclear chromatin condensation or fragmentation and this effect was suppressed by PC1 
(100 nM) treatment.
It was previously reported that PC1 is able to reduce PROK2 up-regulation in DRG neurons and in 
activated astrocytes of spinal cord following nerve injury22,27. qRT-PCR experiments demonstrated, also 
Figure 1. (A) Aβ 1–42 -induced neurotoxicity CNs (1 × 106 cells/well) were treated at 12 DIV with different 
Aβ 1–42 concentrations (5, 10, 20 μ M) and then assayed for cell viability 48 h later. Data represent mean 
(± SEM) from at least 4 independent experiments run in duplicate. Statistically significant differences were 
calculated by one-way analysis of variance (ANOVA) for repeated measures followed by Bonferroni’s test 
for multiple comparisons (*p < 0.05, **p < 0.01 vs CTR). (B) Caspase 3 involvement in Aβ 1–42 -induced 
apoptosis Immunoreactive signal of 17/19 kDa caspase 3 active fragment (Asp 175) from control and Aβ 1–42 
(20 μ M) treated cells, normalized against β −actin, run in duplicate. Molecular mass markers (kDa) are 
shown on the right.
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in this system, that co-incubation with Aβ 1–42 and PC1 (100 nM) prevented the Aβ -induced PROK2 
mRNA up-regulation (Fig.  5A). To confirm these data at protein level, we performed immunofluores-
cence studies looking for the localization of PROK2 in CNs treated with PC1 alone or in the presence 
of Aβ for 48 h. As shown in Fig. 5B, PROK2 immunofluorescence was clearly higher in Aβ -treated than 
in PC1/Aβ -treated neurons.
Neurotoxic activity of Bv8 (PROK2). The antagonistic effect of PC1 on Aβ -induced toxicity led us 
to hypothesize that prokineticins could exert a toxic activity on CNs. To this aim, CNs were treated with 
different concentrations of Bv8 for 48 h. Quantitative analysis revealed that Bv8 (0.001, 0.01, 0.1, 1 and 
10 nM) dose-dependently reduced cell viability, inducing 19.5 ± 1.6%, 46 ± 4%, 38.5 ± 4.4, 24 ± 5.7 and 
26 ± 4.4% reduction of viable cells, as compared to control conditions (Fig. 6). To confirm the activity 
of PC1 on its own agonist, we have co-incubated CNs with PC1 (100 nM) and the most effective con-
centration of Bv8 (0.01 nM). As shown in the same figure, PC1 completely reversed Bv8 toxic activity.
Figure 2. Aβ1–42 effect on PROK2, PKR1 and PKR2 mRNA. Relative PROK2, PKR1 and PKR2 mRNA levels 
were determined by qRT-PCR in CNs (1 × 106 cells/well) treated at 12 DIV with Aβ 1–42 (20 μ M) for different 
times (A–C), in cortex (D–F) and hippocampus (G–I) from Aβ 1–42 injected rats at different time points. 
The mRNA expression levels were expressed in relation to β -actina and presented as fold of increase relative 
to control cultures or Sham rats. Data represent means (± SEM) from at least 4 independent experimental 
points run in triplicate and statistically significant differences were calculated by one-way analysis of 
variance (ANOVA) for repeated measures followed by Bonferroni’s test for multiple comparisons (*p < 0.05, 
**p < 0.01 vs CTR or sham).
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PC1 prevents LTP impairment in Tg2576 hippocampal slices. Previous studies from our group28 
and others29 have shown that the magnitude of LTP, induced with a high-frequency stimulation protocol, 
is impaired in the hippocampus of adult Tg2576 (TG) mouse model of AD compared with age-matched 
wild-type (WT) controls.
Here we recorded field excitatory post-synaptic potentials (fEPSPs) from the stratum radiatum of 
the CA1 area upon stimulation of the Shaffer collaterals pathway every 30 s, a test stimulation intensity 
attaining a half-maximal response. In agreement with our previous report indicating a similar efficacy 
of the basal synaptic transmission in WT and TG mice28, the input-output curves in WT and TG slices 
was not significantly different (data not shown). Similarly, the paired-pulse facilitation (PPF) paradigm, 
a presynaptically mediated short-term enhancement of transmission, was unaffected in all the conditions 
tested (p > 0.05, Fig. 7A,B).
Figure 3. PROK2, PKR1 and PKR2 protein localization in control conditions and after Aβ1–42 treatment. 
Representative confocal images of cultured mixed cortical neurons (CNs) stained with anti-PROK2 (A–D) 
or anti PKR1 (E–H) or anti PKR2 antibodies (I–L) (red) in control conditions (CTRL) and after 48 h Aβ 1–42 
treatment (Aβ ). Neurons were stained with NeuN (green), astrocytes with GFAP (green), and nuclei with 
Hoecsht (blue). Panel (A–D) PROK2 low to medium immunoreactivity was found in neuronal cell bodies 
and astrocytes processes (arrows) in control conditions (first row) which increased after Aβ 1–42 treatment 
mainly in the cell bodies (second row: arrow). Panel (E–H) PKR1 immunoreactivity was undetectable 
(first row) under control conditions in both neurons and astrocytes. After Aβ 1–42 treatment PKR1 
immunoreactivity displayed a selective neuronal increase confined to putative endoplasmic reticulus-Golgi 
complex (arrows) while astrocytes were still devoid of staining (arrowheads). Please note, close to astrocytes 
there are some PKR1 positive neurons (arrows). Panel (I–L) Very low PKR2 immunoreactivity was detected 
under control conditions while, after Aβ 1–42 treatment increased in neuronal cell bodies and astrocyte 
processes (arrows). Note the selective increase in a dying cell body surrounded by astrocytic processes 
(arrowheads). Scale bar: 15 μ m.
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Figure 4. (A) Effect of PC1 against Aβ neurotoxicity CNs (1 × 106 cells/well) were treated at 12 DIV with 
Aβ 1–42 (20 μ M) alone or in the presence of increasing concentrations of PC1 (50, 100, 250, 500 nM) and 
then assayed for cell viability 48 h later. Data from the same concentrations of PC1 alone are also shown. 
Data represent mean (± SEM) from at least 4 independent experiments run in duplicate. (B) Protective 
effect of PC1 on nuclear condensation induced by Aβ 1–42 in terms of Hoechst staining Representative 
immunofluorescence photomicrographs showing cortical cells stained with Hoechst in control conditions 
(CTR), after 48 h incubation with Aβ 1–42 (20 μ M) (Aβ ), simultaneously exposed to Aβ 1–42 and PC1 (100 nM) 
for 48 h. Histogram shows quantification of Hoechst-stained (apoptotic) neurons for each treatment. Five 
fields were selected for each treatment from three independent experiments (n = 3). Data represent means 
(± SEM) from at least 4 independent experiments run in duplicate and statistically significant differences 
were calculated by one-way analysis of variance (ANOVA) for repeated measures followed by Bonferroni’s 
test for multiple comparisons (**p < 0.01 versus CTR; #p < 0.01 versus Aβ 1–42).
Figure 5. PC1 effect on PROK2 up-regulation. (A) Relative PROK2 mRNA levels were determined 
by qRT-PCR in CNs (1 × 106 cells/well) treated for 6 h with Aβ 1–42 (20 μ M), PC1 (100 nM), alone or in 
combination. The mRNA expression levels were expressed in relation to b-actina and presented as fold 
of increase relative to controls (controls Ct: 28.3 ± 0.1. Data represent means (± SEM) from at least 2 
independent experiments run in triplicate and statistically significant differences were calculated by one-way 
analysis of variance (ANOVA) for repeated measures followed by Bonferroni’s test for multiple comparisons 
(*p < 0.05 vs CTR). (B) Representative immunofluorescence photomicrographs of cultured mixed cortical 
neurons (CNs) stained with anti-PROK2 antibody (red) in control conditions (CTRL) and after 48 h Aβ 1–42 
treatment (Aβ ) alone or in the presence of PC1 (200 nM). Neurons were stained with NeuN (green), and 
nuclei with Hoecsht (blue). Note the cytoplasmatic increase in PROK2 which is reversed by PC1 treatment. 
Scale bar: 15 μ m.
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However, LTP produced by high-frequency stimulation (100 Hz, 1 s), was decreased in TG mice 
(123 ± 10) when compared to WT controls (145 ± 10) (p < 0.05, Fig. 7C,D). To test the hypothesis that 
pharmacological inhibition of PKR rescues synaptic plasticity impairment, we measured LTP in acute TG 
hippocampal slices in the presence of the PK receptor antagonist PC1 (50 nM), or vehicle. We found that 
the degree of potentiation in WT slices (145 ± 10) was independent from the presence of PC1 (139 ± 10) 
(p > 0.05, Fig. 7C), indicating that PK blockade does not affect synaptic plasticity in physiological condi-
tions. Notably, LTP in PC1-treated TG hippocampal slices was significantly rescued (151 ± 8) compared 
to vehicle-incubated TG slices (123 ± 10) (p < 0.05, Fig. 7D), suggesting that inhibition of PK receptors 
in TG neurons is sufficient to restore synaptic plasticity to WT levels.
PC1 reverts Aβ-induced toxicity in hippocampal cultures. Since PC1 was able to restore synaptic 
plasticity in the hippocampus of adult Tg2576 mice, we extended the study of PC1 against Aβ 1–42 toxic-
ity in hippocampal primary cultures (HNs). Quantitative analysis revealed that incubation of HNs with 
Aβ 1–42 (20 μ M) for 48 h caused ~ 50% reduction in the number of surviving cells, as compared to control 
cells (CTR). PC1 (100 nM) significantly reduced the Aβ 1–42 toxicity, inducing 28.1 ± 2.9% increase in cell 
viability, as compared to Aβ condition (Additional Fig. 2).
Discussion
Neuropathological hallmarks of AD correlate with the presence of soluble Aβ oligomers as the principal 
neurotoxic agent30,31. Aβ has been so far one of the most important targets for the development of AD 
drugs32,33 so, molecules able to counteract Aβ toxicity will be potential therapeutic agents.
It has been proposed that Aβ plaques stimulate a chronic inflammatory reaction6. Neuroinflammation 
clearly occurs in pathologically vulnerable regions of the AD brain, with increased expression of acute 
phase proteins and proinflammatory mediators, which are hardly evident in the normal brain5,34,35. 
Indeed, several chemokines and chemokine receptors have been found to be up-regulated in the AD 
brain14.
The study here presented shows that the chemokine prokineticin 2 (PROK2) and its receptors are 
involved in Aβ toxicity both in vitro and in vivo. Indeed, our results demonstrated that mRNA and 
protein levels of PROK2, PKR1 and PKR2 are significantly modified by Aβ treatment, suggesting that 
modulation of prokineticin system could be a general response to Aβ injury.
Neurons are not the only cell type in the brain affected in AD; vulnerable brain regions exhibit acti-
vated microglial cells and astrocytes, which often associate with amyloid deposits, suggesting a central 
role of these non-neuronal cells in AD pathology36,37. Different cell types including neurons may pro-
duce chemokines, however, the main neural cells producing chemokines in response to Aβ seem to be 
astrocytes38–40. Accordingly, PROK2 immunoreactivity is significantly increased in response to Aβ , in 
both neurons and astrocytes. Also the prokineticin receptors, almost absent in control conditions, are 
increased after Aβ stimulation: PKR1 immunoreactivity being mainly increased in neurons and PKR2 in 
both cell types.
The functional involvement of the PK system in Aβ toxicity was further demonstrated by the ability of 
PC1, a non-peptide antagonist of the prokineticin receptors41–43, to prevent Aβ toxicity and by the ability 
of Bv8, the amphibian homologue of the mammalian PROK2, to induce apoptosis comparable to that 
induced by Aβ , in cortical brain cultures. The Bv8-inuced apoptosis was prevented by co-administration 
of PC1, as well.
The here demonstrated pro-apoptotic effect of Bv8 disagrees with previous data showing that Bv8 pro-
tects against Oxigen Glucose Deprivation stimulated ischemia (Pellegrini, personal communication) and 
Figure 6. Effect of Bv8. CNs (1 × 106 cells/well) were treated at 12 DIV with different concentrations of 
Bv8, alone or in the presence of PC1 (100 nM) and then assayed for cell viability 48 h later. Data from the 
corresponding concentrations of PC1 alone are also shown. Data represent mean (± SEM) from at least 3 
independent experiments run in duplicate. Statistically significant differences were calculated by one-way 
analysis of variance (ANOVA) for repeated measures followed by Bonferroni’s test for multiple comparisons 
(**p < 0.01 vs CTR; #p < 0.01 ves Bv8 0.01 nM).
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against NMDA-induced excitotoxicity in murine cortical cultures44, and PROK2 protects cardiomyocytes 
against oxidative stress45. It is worthy of note that, whereas the Bv8 protective effects were obtained with 
nanomolar concentrations (10–100 nM), the Bv8 neurotoxic activity, observed in our experiments, was 
achieved with picomolar concentrations (0.01 and 0.1 nM), while higher concentrations did not seem 
to be toxic. Such low concentrations could be compatible with the small amount of PROK2 eventually 
released by Aβ treatment. PKR1 signaling regulates its own ligand expression18,22,42 establishing an auto-
crine and paracrine loop.
Under normal conditions, activation of prokineticin receptors has been shown to stimulate the Erk1,2/
MAPK and Akt pathways20,44,46, which have been mostly associated with cell survival but which also can 
Figure 7. Effect of PC-1 on LTP impairment in Tg2576 mice. Paired pulse ratios (slope of second 
EPSP/slope of first EPSP) were plotted as a function of the inter-pulse interval for 6–9 month old non-
transgenic (panel A) and Tg2576 (panel B) mice. At least 11 slices from 8 different mice are shown for each 
experimental condition. No significant differences between non-transgenic and Tg2576 mice, and between 
treatment groups were detected. Superimposed pooled data representing normalized changes in the field 
potential slope (± SEM) induced by HFS (100 Hz, 1 s) are shown for non-transgenic (panel (C)) and Tg2576 
(panel (D)) mice. At least 7 slices from 7 different mice are shown for each experimental condition. A 
significant reduction of LTP in Tg2576 compared to non-transgenic mice was observed (p < 0.05). Perfusion 
with PC-1 (50 nM) was able to rescue LTP impairment in Tg2576 mice (p < 0.05), but had no effect in 
slices from wild-type controls. PC-1 was continuously bath applied to hippocampal slices throughout the 
experiment.
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exert deleterious effect as in ischemia and inflammation. PROK2, such as Bv8, has comparable affinity 
for either receptors but activates more efficiently the PKR146,47 which is up-regulated in neurons, too. 
Hence PROK2, at different concentrations and/or during insult conditions, might activate differential 
signaling26.
Interestingly, in rat embryo of 18 pc, both the receptors are highly expressed in the neuroepithelium 
lining brain ventricles but the PKR1 expression is significantly decreased in brain cortex of neonatal rats, 
and apparently lacks in brain cortex of adult rats, whereas PKR2 is still expressed at high levels in the 
cortex and other regions of forebrain48. This suggests that developmental apoptotic processes hit mainly 
the PKR1 expressing cells. Hence the upregulation of this receptor, induced mainly in neuronal cells by 
toxic insult, might be responsible for neuronal apoptosis, whereas PKR2 might mediate protective sign-
aling, triggered by the protective (10–100 nM) concentrations of Bv8.
Here we demonstrated that PC1 concentration-dependently reversed Aβ toxicity. Previous data 
acquired with PC1 clearly indicated that it is able to reduce expression and storage of PROK222,27 in 
cells and tissues. This mechanism of action was confirmed at both mRNA and protein level, in here 
reported experiments demonstrating that the increased amount of PROK2 into neurons is significantly 
reduced by PC1 treatment. Hence, block of PK receptors by PC1 reduces PROK2 levels, so impairing 
the pro-apoptotic signaling.
The ability of PC1 to antagonize Aβ toxicity on the one hand, and LTP impairment in the APP 
Tg2576 mouse model of AD on the other, suggests that injury-induced PROK2 expression is deleterious 
and that blocking of the prokineticin system may be therapeutic. In line with this, several chemokine 
signaling molecules are known to modulate cognitive function and synaptic plasticity, either in physio-
logical and pathological conditions49,50. Accordingly, the selective targeting of the chemokine system has 
proven beneficial in diseases associated with synaptic dysfunction and memory impairment, including 
AD51. Certainly, the possible effects of PROK2 dysregulation at the synaptic level remain largely unex-
plored and might involve complex mechanisms. For example, previous electrophysiological experiments 
have demonstrated that PROK2 might reduce the GABAergic function52,53 or modulate voltage-gated 
ion channels54, the balance of which finely regulates intrinsic excitability and synaptic plasticity events. 
Thus, application of PC1 might rescue LTP impairment in the Tg2576 model by preserving synaptic 
homeostasis and vulnerability to the PROK2 insult.
Taken together, these results indicate that PROK2 plays a role in Aβ -mediated neuronal death both 
in vitro and in vivo, representing a new approach in the elucidation of AD etiopathology.
However, further studies will be necessary to assess whether activation of PK signaling indeed is 
involved in AD and whether PROK2 antagonists could actually be used as a therapeutic strategy.
Methods
Chemicals. Aβ 1–42 was purchased from Abcam (Abcam, Cambridge, UK). Aβ peptide stock solutions 
at a concentation of 1 mg/ml were prepared in PBS (0.01 M NaH2PO4, 0.15 M NaCl, pH 7.4) and stored 
to − 20 °C. Aliquots of Aβ peptides were allowed aggregating by incubation at 37 °C for 72 h before in 
vivo infusion55. In the Additional Fig.  3, Western blot results showed that Aβ oligomers preparations 
comprise a mixture of dimers, trimers, and tetramers (from 4 to 20 kDa) and larger oligomers high-mo-
lecular-weight (molecular masses ranging from 70 to 100 kDa). All other reagents were also from Sigma 
(St. Louis, MO, Missouri), if not specifically reported.
Surgical procedures. All procedures were approved by the Italian Ministry of Health (Rome, Italy) 
and performed in compliance with the guidelines of the US National Institutes of Health and the Italian 
Ministry of Health (D.L.116/92). All efforts were made to minimize the number of animals and their 
suffering.
Male adult Sprague-Dawley rats (Charles River, Como, Italy) weighting 250–275 g were housed in indi-
vidual plastic cages under optimum light conditions (12:12 h light–dark cycle), temperature (22 ± 2 °C), 
and humidity (52 ± 2%), with food and water provided ad libitum. Under ketamine-xylazine anaesthesia 
(60 + 10 mg/kg, i.p.), each rat was implanted surgically with a plastic guide cannula (Linca, Tel-Aviv, 
Israel), stereotaxically inserted through a skull hole drilled over the left lateral ventricle of the brain 
(1 mm caudal to and 1.8 mm lateral to the bregma). The cannula was screwed into the skull hole and 
secured to the bone with dental cement. After one week-recovery from surgery, Aβ 1–42 (1 nmol) or saline 
solution were intracerebroventricularly (i.c.v.) injected, in a constant volume of 5 μ l in awake rats, using 
a 10-μ l Hamilton syringe fitted with a 26-gauge needle that was inserted through the guide cannula to 
a depth of 4.2 mm below the external surface of the skull. The needle was left in place for 10 s after the 
end of the injection to avoid reflux of the solute.
RNA purification, reverse transcription, and RNA determination by quantitative RT-PCR. For 
the in vitro studies, cortical cultures were treated with Aβ 1–42 (20 μ M) for 6, 12 and 24 h. For in vivo stud-
ies, animals were euthanized 3, 6, 24 and 48 h following Aβ 1–42 (1 nmol) i.c.v. injection. Total RNA was 
extracted using the TRIzol solution Invitrogen (Carlsbad, CA, USA), according to the manufacturer’s 
instructions. For in vivo samples, tissues were homogenized using a power homogenizer and insoluble 
material was removed by centrifugation at 12.000 g for 10 min at 8 °C. To obtain cDNA, 2 μ g total RNA 
was reverse transcribed in MLV reverse transcription buffer (Promega, Madison, WI) containing the 
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following: 40 μ g/ml random primers (Promega, Madison, WI), 1 mM dNTP, 40 μ g/ml of Recombinant 
RNasin Ribonuclease Inhibitor (Promega, Madison, WI), and MLV reverse transcriptase (Promega, 
Madison, WI) in a final volume of 25 μ l. The reaction was incubated at 37 °C for 60 min. Messenger 
RNA expression was quantitatively measured with real time quantitative PCR (ABI Prism 7700 Sequence 
Detector; Perkin Elmer Applied Biosystems, Foster City, CA) using SYBR Select MasterMix fluorescence 
(Applied Biosystems).
The primer sequences used in this study were as following: for rat PROK2, forward 
5′ -TCATCACCGGGGCTTGCG -3′ , reverse 5′ -TAACTTTCCGAGTCAGGG -3′ ; for rat PKR1, forward 
5′ -CGCACCGTCTCCCTCTAC-3 and reverse 5′ - GTTTGACACTTCATCCGCG-3′ ; for rat PKR2, for-
ward 5′ -CTCCGTCAACTACCTTCGTA-3′ and reverse 5′ -GAGGCGGTCTGGTAATTCA-3′ .
The internal reference Tata Binding Protein (TBP) primer was purchased from Invitrogen. Real time 
PCR amplification and product detection was performed using an ABI PRISM 7900 FAST REAL TIME 
PCR (Applied Biosystems, Fostercity, CA, USA). Each assay included a standard curve sample in dupli-
cate, a no template control, and the cDNA sample from treated cells in triplicate for each point. For each 
set of primers, a no template control and a no reverse transcriptase control was included. The thermal 
cycling conditions were: 95 °C, 2 min for denaturation, followed by 40 cycles of 95 °C, 15 sec, 60 °C, 1 min. 
Post-amplification dissociation curves were performed to verify the presence of a single amplification 
product and the absence of genomic DNA contamination. The Ct value of the specific gene of interest 
was normalized to the Ct value of the endogenous control, β − actin, and the comparative method (2-∆∆Ct) 
was then applied using control group as calibrator.
Primary cortical cultures. Cortical cultures. Cortical cultures were prepared from brains of 
embryonic day 17–18 (E17/E18) embryos from timed pregnant Wistar rats (Charles River), as previ-
ously reported40. In brief, cortex was dissected out in Hanks’ balanced salt solution buffered with Hepes 
and dissociated via trypsin treatment. Cells were plated at 1 × 106 cells on 3.5-cm dishes precoated 
with poly-L-lysine. After 2 days of culturing in neurobasal medium with B-27 supplement (0.5 mM 
L-glutamine, 1% antibiotic penicillin/streptomycin), half of the medium was changed every 3–4 days. 
All experimental treatments were performed on 12-day “in vitro” (DIV) cultures in Neurobasal + ½ 
B27 fresh medium. The culture cell composition was examined using immunocytochemical staining for 
neurons (NeuN antibody, Sigma, 1: 200), astrocytes (GFAP antibody, Sigma 1:400) and microglia (Iba1 
antibody, Abcam 1: 200) with DAPI nuclear staining. Mixed cultures contain about 50% NeuN+ cells, 
45% GFAP+ cells and 4% of Iba1+ cells.
Hippocampal cultures. Hippocampal cultures were prepared from brain of embryos Wistar rats (Charles 
River) at embryonic day 17–18 (E17/E18), as previously reported56. Briefly, hippocampus was dissected 
out in Hanks’ balanced salt solution buffered with Hepes and dissociated via trypsin treatment. Cells 
were plated at 1 × 106 cells on 3.5-cm dishes precoated with poly-L-lysine. After 2 days of culturing in 
neurobasal medium with B-27 supplement (0.5 mM L-glutamine, 1% antibiotic penicillin/streptomycin), 
half of the medium was changed every 3–4 days. All experimental treatments were performed on 12-day 
in vitro (DIV) cultures in Neurobasal + ½ B27 fresh medium.
Cell viability and nuclear morphology. Cell viability was assessed by counting the number of intact 
nuclei according to the method previously described57. Briefly, the culture medium was removed and 
replaced with 0.5 ml of a detergent containing lysing solution (0.5% ethylhexadecyldimethylammonium 
bromide, 0.28% acetic acid, 0.5% Triton X-100, 3 mM NaCl, 2 mM MgCl2, in phosphate-buffered saline 
(PBS) pH 7.4 diluted 1/10). After 2 min, cells were collected and the solution consisted of a uniform 
suspension of single, intact, viable nuclei that were then quantified by counting in hemocytometer since 
the detergent-containing solution is able to dissolve the nuclei of the cells that are dying, while healthy 
cells appear as phase-bright intact circles surrounded by a dark ring. Broken or damaged nuclei were 
not included in the count.
Alternatively, cortical cultures were fixed in 4% paraformaldehyde and permeabilized with 0.2% 
Triton X-100 in Tris HCl 0.1 M pH 7.4 for 5 min and then incubated with Hoechst 33258 (0.25 μ g/ml) 
for 5 min at room temperature. After washing with PBS, the percentage of shrunken and condensed 
nuclei was assessed. Apoptotic nuclei were then visualized by a Leica fluorescent photomicroscope and 
scored by counting 12 microscopic fields per coverslip in 2 coverslips from 4 experiments.
Western blotting. For cytoplasmic lysates, neurons were washed twice with ice-cold PBS, lysed in 
lysis buffer (1% NP40, 50 mM Tris-HCl, pH8) and cetrifuged before the addition of 1X protease inhib-
itor mixture. Protein concentration was measured using a Biorad DC protein assay kit (Bio-Rad) and 
equivalent amounts of protein (10–30 μ g) were separated on 4–12% Bis-Tris SDS-PAGE gels (Invitrogen), 
blocked with 5% milk for 30 min and then incubated overnight with anti rabbit cleaved caspase 3 (Asp175) 
(Cell Signaling 1:1000) or anti β -actin (Sigma (1:10000) or monoclonal anti Aβ (6E10, Covance 1:500).
Incubation with anti-rabbit secondary antibodies peroxidase-coupled was performed for 1 h at 
room temperature. Immunoreactivity was developed with enhanced chemiluminescence (ECL system; 
Amersham, Arlington Heights, IL) and visualized by autoradiography.
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Immunofluorescence. Living mixed cortical cells were stained for 1 h at 4 °C using rabbit pol-
yclonal anti-PKR1 or anti-PKR2 antibodies 1:400 in PBS (Alomone Labs, Jerusalem, Israel), washed 
in PBS and incubated with a goat anti-rabbit rhodamine-conjugated secondary antibody (Sigma) for 
30 min at room temperature. This procedure allowed us to specifically target surface protein expres-
sion. Cells were then fixed in 4% (w/v in PBS) paraformaldehyde for 10 min at room temperature 
on immunofluorescence-labeled coverslips. For PROK2 immunofluorescence, CNs were first fixed in 
4% (w/v in PBS) paraformaldehyde following the above procedure, incubated with rabbit polyclonal 
anti-PROK2 antibody (Abcam, Cambridge, UK 1:400), washed in PBS and incubated with a goat 
anti-rabbit rhodamine-conjugated secondary antibody (Sigma) for 30 min at room temperature.
CNs cells were then incubated with mouse anti-NeuN (Sigma, 1:200 dilution) or mouse anti-GFAP 
(Sigma, 1:400 dilution) overnight at 4 °C and with a goat anti-mouse alexa-488 conjugated secondary 
antibody (Sigma, 1:400) for 30 min at room temperature. For nuclei visualization, coverslips were incu-
bated with Hoecsht 33258 (0,25 μ g/ml) for 5 min at room temperature. Cells were visualized by a con-
focal laser scanning microscope (Leica SP5, Leica Microsystems, Wetzlar, Germany). Final figures were 
assembled by using Adobe Photoshop 7 and Adobe Illustrator 10.
Extracellular recordings. Electrophysiological recordings were performed in male Tg2576 trans-
genic mice aged 6–9 months using standard procedures58. Tg2576 mice and their non-transgenic lit-
termates were purchased from Taconic Europe (Lille Skensved, Denmark). Preparation of hippocampal 
slices was performed in accordance with the European Communities Council Directive (86/609/EEC). 
Vibratome-cut parasagittal slices (400 μ m) were prepared, incubated for 1 h and then transferred to a 
recording chamber submerged in a continuously flowing artificial CSF (30 °C, 2–3 ml/min) gassed with 
95% O2 and 5% CO2. The composition of the control solution was (in mM): 126 NaCl, 2.5 KCl, 1.2 
MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 11 glucose, 25 NaHCO3. fEPSPs were recorded in the stratum radia-
tum of the CA1 using glass microelectrodes (1–5 MΩ ) filled with artificial CSF. Paired pulse facilitation 
(PPF) was assessed at inter-stimulus intervals ranging from 20 to 500 ms. An additional 30 min baseline 
period was obtained before attempting to induce long-term potentiation (LTP). LTP was induced by a 
high- frequency stimulation (HFS) protocol (1 train, 100 Hz, 1 s) and the effect of conditioning train was 
expressed as the mean (± SEM) percentage of baseline EPSP slopes measured at 60 min after stimulation 
protocol. Statistical analysis was evaluated by unpaired Student’s t test (significance was set at p < 0.05).
Data analysis. Statistical analysis was performed using SPSS 11.0.0 for Windows (SPSS Inc., USA). 
All results are expressed as mean + SEM, with n the number of independent experiments. The signifi-
cance of the effect was performed by one-way analysis of variance (ANOVA) followed by Bonferroni’s 
test for multiple comparisons. The significance level was set at p < 0.05 (*) and p < 0.01 (**).
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